Pharmaceutical News

RSS

Inhibition of SARS-CoV-2 by bentonite-based nasal spray

Therefore, the nose is an important target for prophylaxis and also for therapy. In a recent study posted to the bioRxiv* preprint server, Fabio Fais et al. developed a safe and easy-to-use nasal spray, AM-301, a medical device marketed as Bentrio, to protect against infection by SARS-CoV-2 and potentially other viruses.

19 Jul 2021

Plant-based vaccines for COVID-19 and other viruses

A review published in the journal Vaccines, explored the history and current status of plant-produced vaccine candidates against enveloped viruses, focusing on virus-like particles (VLPs), which mimic authentic viral structures without containing infectious genetic material.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

Broad-spectrum antibiotic no more effective than placebo in preventing COVID-19 symptoms

A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.

16 Jul 2021

Taking "z-drugs" with opioids increases risk of death

A new study by Vanderbilt University Medical Center researchers of more the 400,000 Medicare patients taking medications for insomnia found that the risk of death is increased when either benzodiazepines or "z-drugs" are taken with opioids.

16 Jul 2021

COVID-19 researchers review 184 drug repurposing candidates

New research describes the use of integrative bioinformatics analyses of transcriptomic profiles for COVID-19 therapeutics.

15 Jul 2021

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Now, new research published in the journal Hippokratia focuses on assisting the ongoing COVID-19 therapeutic research by developing a new method to identify active compounds that have the potential to fight against COVID-19 infection.

15 Jul 2021

Full intensity heparin has value in treating hospitalized COVID-19 patients

Results from the RAPID clinical trial suggest heparin may lower the risk of death from moderate COVID-19 infection by 78%. Heparin also significantly increased the number of days patients went without ventilation or requiring organ support.

14 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Molecular dynamic analysis of SARS-CoV-2 inhibitors

A new study reports the results of molecular dynamic simulations that were performed in an effort to identify new drugs that could be effective against SARS-CoV-2.

13 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Early anticlotting therapy offers benefits for moderately ill patients with Covid-19

COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death.

13 Jul 2021

GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections

The Global Antibiotic Research and Development Partnership, the Clinton Health Access Initiative and Shionogi & Co., Ltd today announced a Memorandum of Understanding to accelerate access, including in low- and middle-income countries, to the antibiotic cefiderocol for bacterial infections in patients with limited treatment options.

13 Jul 2021

Why we may never know whether the $56,000-a-year Alzheimer’s drug actually works

The Food and Drug Administration's approval in June of a drug purporting to slow the progression of Alzheimer's disease was widely celebrated, but it also touched off alarms.

12 Jul 2021

What is behind the inconsistent results of COVID-19 clinical trials?

“Most clinical studies of antiviral drugs for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have failed to observe a statistically significant effect, which may be due to poor designs of clinical trials.”

12 Jul 2021

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

The drugmaker Pfizer, one of the companies behind the Pfizer-BioNTech vaccine, or BNT162b2, awaits the green light to develop a COVID-19 booster shot that can protect against emerging variants. Pfizer’s COVID-19 vaccine has been shown to be 95% effective in an ongoing large-scale clinical trial against the original SARS-CoV-2 strain.

11 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Doctors weigh pros and cons of prescribing hot-button Alzheimer’s drug

As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer's disease approved in 18 years, patients want to know: "Will this medication help me — and how much?"

9 Jul 2021

Pharmaceutical News

Inhibition of SARS-CoV-2 by bentonite-based nasal spray

Plant-based vaccines for COVID-19 and other viruses

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

Broad-spectrum antibiotic no more effective than placebo in preventing COVID-19 symptoms

Taking "z-drugs" with opioids increases risk of death

COVID-19 researchers review 184 drug repurposing candidates

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Full intensity heparin has value in treating hospitalized COVID-19 patients

New OMV-based COVID-19 vaccine candidate proves effective in mice

Molecular dynamic analysis of SARS-CoV-2 inhibitors

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Early anticlotting therapy offers benefits for moderately ill patients with Covid-19

GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections

Why we may never know whether the $56,000-a-year Alzheimer’s drug actually works

What is behind the inconsistent results of COVID-19 clinical trials?

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Doctors weigh pros and cons of prescribing hot-button Alzheimer’s drug

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News